Although the use of oral anticoagulants (vitamin K antagonists) has been abandoned in primary cardiovascular prevention due to lack of a favorable benefit-to-risk ratio, the indications for aspirin use in this setting continue to be a source of major debate, with major international guidelines providing conflicting recommendations. Here, we review the evidence in favor and against aspirin therapy in primary prevention based on the evidence accumulated so far, including recent data linking aspirin with cancer protection. While awaiting the results of several ongoing studies, we argue for a pragmatic approach to using low-dose aspirin in primary cardiovascular prevention and suggest its use in patients at high cardiovascular risk, defined as $2 major cardiovascular events (death, myocardial infarction, or stroke) projected per 100 person-years, who are not at increased risk of bleeding. (J Am Coll Cardiol 2014;64:319-27)
T he recognition that thrombosis plays an important role in acute cardiovascular disease (CVD) (2, 3) has resulted in a large number of clinical trials on the effectiveness of antithrombotic drugs in CVD prevention. The benefit of antiplatelet drugs (aspirin and P2Y 12 inhibitors) in reducing mortality and/or new cardiovascular events in patients with prior CVD (secondary prevention) with an acceptable risk of bleeding has been clearly shown (4, 5) .
However, in patients without prior CVD (primary prevention), the indication for antithrombotic drugs is still unclear. In this population, aspirin-the only antithrombotic drug studied in sufficiently large patient cohorts-produces a statistically significant reduction in the risk of a first myocardial infarction (MI), but increases the risk of both gastrointestinal (GI) bleeding and hemorrhagic stroke (6) 
ASSESSING BASELINE RISK
In primary CVD prevention, in which the risk of developing atherothrombotic events is generally low, it is essential to estimate the individual baseline risk of such events and carefully balance this against the risk of adverse outcomes related to therapy.
Commonly-used tools to assess baseline risk are the Framingham coronary heart disease (CHD) risk score (8) , the recently released American College of Cardiology/American Heart Association (AHA/ACC) Task Force risk equations (9), ESC's SCORE (Systematic Coronary Risk Evaluation), or national risk charts.
Some tools assess the risk of cardiovascular death, whereas others assess all major cardiovascular events. The Framingham CHD risk score predicts the 10-year risk of developing a coronary event (composite of MI and coronary death), and individuals are categorized as low (<10%), moderate (10% to 20%), or high (>20%) risk. Conversely, the SCORE system, recommended in the ESC guidelines (7), estimates the 10-year risk of a fatal atherosclerotic event: individuals are considered at low risk with a SCORE <1%, at moderate risk with a SCORE $1%
and <5%, at high risk with a SCORE $5% and <10%, and at very high risk with a SCORE $10% (7).
Clearly, the risk of total fatal and nonfatal events is higher than that of fatal events only. At a 5% risk of fatal events, the total event risk is approximately 15% (7). This 3-fold multiplier is somewhat smaller in the elderly, in whom a first event is more likely to be fatal.
ASPIRIN IN PRIMARY CVD PREVENTION
The only antithrombotic drugs investigated for primary CVD prevention are vitamin K antagonists, which were investigated in only 1 trial and are currently abandoned (Online Appendix), and acetyl salicylic acid (aspirin). Aspirin has been studied in 9 large-scale RCTs (10) (11) (12) (13) (14) (15) (16) (17) (18) , including more than 100,000 participants ( Table 1 , Online Appendix). Table 1) . These trials were somewhat nonhomogeneous with the previous ones, as they included individuals who, although asymptomatic, were at higher risk because of pre-existing diabetes, asymptomatic PAD, or both. In these metaanalyses, all-cause-but not vascular-mortality was slightly but consistently reduced, reiterating a risk ratio of 0.94 with uniform confidence limits (0.88 to 1.00), but without reaching formal significance. These figures compare well with those of the ATT metaanalysis (confidence limits: 0.88 to 1.02) (6) . The claim for a significant reduction of mortality is not formally justified by the data and is possibly misleading (24, 25) .
In patients with asymptomatic PAD, a recent systematic review (26) confirmed that no differences were observed between aspirin and placebo for total Aspirin also increases the risk of hemorrhagic stroke. A meta-analysis of 16 placebo-controlled RCTs, comprising a total of 55,462 patients, showed that treatment with aspirin was associated with a relative risk of hemorrhagic stroke of 1.84 (p < 0.001) (28) . In absolute terms, one could predict 12 incident cases of hemorrhagic stroke per 10,000 patients chronically treated with aspirin (29) . The ATT Collaboration reported a statistically significant 22% increased incidence of hemorrhagic stroke in patients on antiplatelet treatment (30) .
ASPIRIN FOR PRIMARY CVD PREVENTION IN DIABETES.
Patients with diabetes have a 2 to 4Â greater risk of cardiovascular events than individuals of the same age and sex without diabetes (31, 32) . Data by Haffner Table 2) .
CURRENT GUIDELINES
The 2012 ESC (7) increasing from primary prevention in young totally healthy individuals, to high-risk primary prevention, and then to secondary prevention (Fig. 1) .
There is indeed no theoretical reason or any evidence suggesting a discontinuity of aspirin effects throughout these categories. The benefit of treatment (saving major cardiovascular events) is clearly superior to the risk (inducing major bleeding) in the setting of secondary cardiovascular prevention. In the lowest risk category of secondary prevention, the stable angina population investigated in the Swedish Angina Pectoris Aspirin Trial (47), the use of aspirin 75 mg/day was associated with a significant 32% reduction in vascular events, a 35% increase in major bleeding, and 9 versus 5 fatal bleeds in the aspirin and placebo groups, respectively, and was judged to be clearly favorable, with 118 vascular events prevented versus 10 patients lost through fatal bleeds for 10,000 patient-years of treatment (47) .
It is hard to imagine that, going down the spectrum of cardiovascular risk from secondary to primary prevention, there would be an immediate drop of the risk/ benefit ratio making aspirin use suddenly unappealing. Nature usually does not make jumps. Indeed, a graphical evaluation of the benefit-risk balance, as portrayed in Figure 1 , indicates a large area of cardiovascular risk in primary prevention where data from trials are lacking, but in whom the benefit may still outweigh the risk. The ongoing trials will try to answer this question. In the meantime, however, taking into account the logical argument of the continuum in primary and secondary prevention, the argument raised that for the entire primary prevention "the balance between vascular events avoided and major bleeds caused by aspirin is substantially uncertain because the risks without aspirin, and hence the absolute benefits of antiplatelet prophylaxis, are at least an order of magnitude lower than in secondary prevention" (48) should not be raised generically.
Additional considerations ( Table 3 ) mostly prompt aspirin use in primary prevention. Particularly worthy of additional discussion are the following:
1. Most models attribute equal weight in terms of patient preference to a nonfatal cardiovascular event (MI and ischemic stroke) and to major bleeding. With the exception of the rare occurrence of hemorrhagic stroke, this is hard to concede.
Although not at all negligible in terms of consequences for deaths and disabilities (49) , the risk of hemorrhagic stroke appears to be around one-fifth of all major bleeding events incurred because of aspirin use (Online Table 1 ), and its fatal consequences are already comprised in total deaths estimates associated with aspirin use, which points toward a net benefit (25).
2. The alleged sex differences, proposed for the aspirin-related protection from cardiovascular events (11), do not seem to hold when the entire evidence is reviewed and analyzed (6).
It is, however, probable that risk scores developed some years ago do not reflect-and likely over- Bleeds induced numerically equal ischemic events prevented.
Although this may be true in some of the primary prevention studies, this is unlikely to hold for high-risk primary prevention, in which no data are so far available and projections ( Fig. 1) would indicate an NNH higher than the NNT.
Bleeds induced have a similar prognostic implication as ischemic events averted. This is, with the exception of the rare occurrence of intracranial hemorrhage (approximately one-fifth of all major bleeds), unlikely to be true, as nonfatal ischemic events averted are mostly "spontaneous" myocardial infarctions and (ischemic) strokes.
Patients' preferences: most patients would prefer nonfatal major bleeding to a nonfatal myocardial infarction or stroke.
Aspirin may reduce the risk of cancer in the long-term, extending the benefit beyond CVD prevention, and so far is underestimated in the relatively short follow-up of CVD prevention studies. aspirin is expected to produce more benefit than risk.
We propose such a threshold at a risk of major cardiovascular events (death, MI, and stroke) $2 per 100 patient-years, assessed through the most accurate and country-specific risk factor estimates. Such a proposal is: 1) logically derived from the previously-described evidence; and 2) a conservative one, privileging safety rather than efficacy. Upon inspection of Beyond routine screenings, we also recommend that additional evidence of risk can be used to prompt doctors and patients to adopt antithrombotic therapy with aspirin in conditions of indecision (52). We also recommend that, after careful transferring of the relevant information to patients, individual values and preferences should be taken into account.
We recognize that across the entire area of high cardiovascular risk in primary prevention, and especially in high-risk primary prevention ($2 major cardiovascular events per 100 patient-years) (Fig. 1) , it is opportune to acquire more data through other placebo-controlled trials, some of which are already ongoing. Particularly problematic areas include diabetic patients or patients with asymptomatic PAD.
The mere presence of either does not appear sufficient for aspirin to confer a benefit clearly exceeding the risk.
CONCLUSIONS AND RECOMMENDATIONS
We recommend that aspirin use in the primary prevention of acute MI and other atherothrombotic cardiovascular events in subjects of both sexes is guided by an assessment of the underlying cardiovascular risk (Grade of Recommendation: I, Level of Evidence: B) (Central Illustration). We suggest that The first step should be an assessment of patient's eligibility to the treatment, by assessing the 10-year risk of major cardiovascular (CV) events (death, myocardial infarction, and stroke), according to local population risk estimates. Eligible patients will be those with an estimated 10-year risk >20%. Patients with a 10-year risk between 10% and 20% will be deemed as "potentially eligible," and those with a risk <10% will be considered noneligible. The second step will be assessing safety in eligible and potentially-eligible patients, through a history of bleeding without reversible causes, and concurrent use of other medications that increase bleeding risk. In the absence of such conditions, patients with a risk >20% should be given low-dose aspirin, and those with a risk 10% to 20% should be engaged in a case-by-case discussion, factoring family history of gastrointestinal cancer (especially colon cancer) and patient values and preferences; particularly motivated patients can then be prescribed low-dose aspirin. Chieti, Italy. E-mail: rdecater@unich.it.
